TNRC6C-AS1 Promotes Thyroid Cancer Progression by Upregulating LPAR5 via miR-513c-5p

References

• ZaballosMA, SantistebanP. Key signaling pathways in thyroid cancer. J Endocrinol. 2017;235(2):R43–r61. doi:10.1530/joe-17-026628838947
   PubMed Web of Science ®Google Scholar
• WangX, ZhangQ, CaiZ, DaiY, MouL. Identification of novel diagnostic biomarkers for thyroid carcinoma. Oncotarget. 2017;8(67):111551–111566. doi:10.18632/oncotarget.2287329340074
   PubMedGoogle Scholar
• LundgrenCI, HallP, DickmanPW, ZedeniusJ. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106(3):524–531. doi:10.1002/cncr.2165316369995
   PubMed Web of Science ®Google Scholar
• XingM, HaugenBR, SchlumbergerM. Progress in molecular-based management of differentiated thyroid cancer. Lancet (London, England). 2013;381(9871):1058–1069. doi:10.1016/s0140-6736(13)60109-9
   PubMed Web of Science ®Google Scholar
• SedaghatiM, KebebewE. Long noncoding RNAs in thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2019;26(5):275–281. doi:10.1097/med.000000000000049731385810
   PubMedGoogle Scholar
• RenganathanA, Felley-BoscoE. Long noncoding RNAs in cancer and therapeutic potential. Adv Exp Med Biol. 2017;1008:199–222. doi:10.1007/978-981-10-5203-3_728815541
   PubMed Web of Science ®Google Scholar
• MuhanhaliD, ZhaiT, JiangJ, AiZ, ZhuW, LingY. Long non-coding antisense RNA TNRC6C-AS1 Is activated in papillary thyroid cancer and promotes cancer progression by suppressing TNRC6C expression. Front Endocrinol (Lausanne). 2018;9:360. doi:10.3389/fendo.2018.0036030038597
   PubMed Web of Science ®Google Scholar
• YangLX, WuJ, GuoML, ZhangY, MaSG. Suppression of long non-coding RNA TNRC6C-AS1 protects against thyroid carcinoma through DNA demethylation of STK4 via the Hippo signalling pathway. Cell Prolif. 2019;52(3):e12564. doi:10.1111/cpr.1256430938030
   PubMed Web of Science ®Google Scholar
• PengX, JiC, TanL, et al. Long non-coding RNA TNRC6C-AS1 promotes methylation of STK4 to inhibit thyroid carcinoma cell apoptosis and autophagy via Hippo signalling pathway. J Cell Mol Med. 2020;24(1):304–316. doi:10.1111/jcmm.1472831657132
   PubMed Web of Science ®Google Scholar
• JalaliS, BhartiyaD, LalwaniMK, SivasubbuS, ScariaV. Systematic transcriptome wide analysis of lncRNA-miRNA interactions. PLoS One. 2013;8(2):e53823. doi:10.1371/journal.pone.005382323405074
   PubMed Web of Science ®Google Scholar
• ZhangH, CaiY, ZhengL, ZhangZ, LinX, JiangN. Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p/KLK7 expression. J Cell Physiol. 2018;233(10):6638–6648. doi:10.1002/jcp.2642529319165
   PubMed Web of Science ®Google Scholar
• HouS, LinQ, GuanF, LinC. LncRNA TNRC6C-AS1 regulates UNC5B in thyroid cancer to influence cell proliferation, migration, and invasion as a competing endogenous RNA of miR-129-5p. J Cell Biochem. 2018;119(10):8304–8316. doi:10.1002/jcb.2686829893424
   PubMed Web of Science ®Google Scholar
• JiaP, WeiE, LiuH, WuT, WangH. Silencing of long non-coding RNA DLX6-AS1 weakens neuroblastoma progression by the miR-513c-5p/PLK4 axis. IUBMB Life. 2020;72(12):2627–2636. doi:10.1002/iub.239233031637
   PubMed Web of Science ®Google Scholar
• ChanJJ, TayY. Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci. 2018;19. doi:10.3390/ijms19051310.
   Web of Science ®Google Scholar
• ZhuX, JiaoJ, ZhouC, et al. LPAR5, GNAT3 and partial amino acid transporters messenger RNA expression patterns in digestive tracts, metabolic organs and muscle tissues of growing goats. Animal. 2019;13(7):1394–1402. doi:10.1017/s175173111800282330378518
   PubMed Web of Science ®Google Scholar
• ArakiM, KitayoshiM, DongY, et al. Inhibitory effects of lysophosphatidic acid receptor-5 on cellular functions of sarcoma cells. Growth Factors (Chur, Switzerland). 2014;32(3–4):117–122. doi:10.3109/08977194.2014.911294
   PubMed Web of Science ®Google Scholar
• WuCY, ZhengC, XiaEJ, et al. Lysophosphatidic acid Receptor 5 (LPAR5) plays a significance role in papillary thyroid cancer via phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (mTOR) pathway. Med Sci Monitor. 2020;26:e919820. doi:10.12659/msm.919820
   PubMed Web of Science ®Google Scholar
• ZhangS, WangQ, HanQ, HanH, LuP. Identification and analysis of genes associated with papillary thyroid carcinoma by bioinformatics methods. Biosci Rep. 2019;39(4):Apr. doi:10.1042/bsr20190083
   Web of Science ®Google Scholar
• LiuL, HeC, ZhouQ, WangG, LvZ, LiuJ. Identification of key genes and pathways of thyroid cancer by integrated bioinformatics analysis. J Cell Physiol. 2019;234(12):23647–23657. doi:10.1002/jcp.2893231169306
   PubMed Web of Science ®Google Scholar
• TangJ, KongD, CuiQ, et al. Bioinformatic analysis and identification of potential prognostic microRNAs and mRNAs in thyroid cancer. Peer J. 2018;6:e4674. doi:10.7717/peerj.467429740512
   PubMed Web of Science ®Google Scholar
• XueG, LinX, WuJF, et al. Identification of key genes of papillary thyroid carcinoma by integrated bioinformatics analysis. Biosci Rep. 2020;40:8. doi:10.1042/bsr20201555
   Web of Science ®Google Scholar
• XiaHL, LvY, XuCW, et al. MiR-513c suppresses neuroblastoma cell migration, invasion, and proliferation through direct targeting glutaminase (GLS). Cancer Biomarkers. 2017;20(4):589–596. doi:10.3233/cbm-17057728800318
   PubMed Web of Science ®Google Scholar
• WangO, HuangY, WuH, ZhengB, LinJ, JinP. LncRNA LOC728196/miR-513c axis facilitates glioma carcinogenesis by targeting TCF7. Gene. 2018;679:119–125. doi:10.1016/j.gene.2018.08.08130179681
   PubMed Web of Science ®Google Scholar
• XuJ, SunT, HuX. microRNA-513c suppresses the proliferation of human glioblastoma cells by repressing low-density lipoprotein receptor-related protein 6. Mol Med Rep. 2015;12(3):4403–4409. doi:10.3892/mmr.2015.391326063413
   PubMed Web of Science ®Google Scholar
• ZhangK, ZhaoZ, YuJ, ChenW, XuQ, ChenL. LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma. J Cell Biochem. 2018;119(7):6045–6056. doi:10.1002/jcb.2680229574975
   PubMed Web of Science ®Google Scholar
• LiuX, PengD, CaoY, et al. Upregulated lncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10 axis. Cancer Gene Ther. 2020. doi:10.1038/s41417-020-00233-0
   Web of Science ®Google Scholar
• LiX, Abdel-MageedAB, MondalD, KandilE. The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid. 2013;23(2):209–218. doi:10.1089/thy.2012.023723273524
   PubMed Web of Science ®Google Scholar
• WenC, YangS, ZhengS, FengX, ChenJ, YangF. Analysis of long non-coding RNA profiled following MC-LR-induced hepatotoxicity using high-throughput sequencing. J Toxicol Environ Health A. 2018;81(22):1165–1172. doi:10.1080/15287394.2018.153271730430930
   PubMed Web of Science ®Google Scholar
• ChuangTD, KhorramO. Expression profiling of lncRNAs, miRNAs, and mRNAs and their differential expression in leiomyoma using next-generation RNA sequencing. Reprod Sci. 2018;25(2):246–255. doi:10.1177/193371911771126528587571
   PubMed Web of Science ®Google Scholar
• HeJH, HanZP, ZouMX, et al. Analyzing the LncRNA, miRNA, and mRNA regulatory network in prostate cancer with bioinformatics software. J Computational Biol. 2018;25(2):146–157. doi:10.1089/cmb.2016.0093
   PubMed Web of Science ®Google Scholar
• LiDY, ChenWJ, LuoL, et al. Prospective lncRNA-miRNA-mRNA regulatory network of long non-coding RNA LINC00968 in non-small cell lung cancer A549 cells: a miRNA microarray and bioinformatics investigation. Int J Mol Med. 2017;40(6):1895–1906. doi:10.3892/ijmm.2017.318729039552
   PubMed Web of Science ®Google Scholar
• MaoY, LiuR, ZhouH, et al. Transcriptome analysis of miRNA-lncRNA-mRNA interactions in the malignant transformation process of gastric cancer initiation. Cancer Gene Ther. 2017;24(6):267–275. doi:10.1038/cgt.2017.1428524153
   PubMed Web of Science ®Google Scholar
• ZhengYQ, MiaoX, LiJ, et al. Trichostatin A alleviates the process of breast carcinoma by downregulating LPAR5. Eur Rev Med Pharmacol Sci. 2020;24(11):6417–6425. doi:10.26355/eurrev_202006_2154032572939
   PubMed Web of Science ®Google Scholar
• ZhangHP, ChenQK, XuJF. LPAR5 stimulates the malignant progression of non-small-cell lung carcinoma by upregulating MLLT11. Eur Rev Med Pharmacol Sci. 2020;24(17):8902–8910. doi:10.26355/eurrev_202009_2283132964980
   PubMed Web of Science ®Google Scholar